Mercator Moves To New Studies Following DANCE Success
Results of DANCE, the first large-scale trial of Mercator’s Bullfrog micro-infusion catheter device, showed local dexamethasone-delivery with Bullfrog yields patient outcomes that compare favorably to that of drug-coated balloons in patients with peripheral artery disease. The company is pursuing more trials of Bullfrog in peripheral artery disease patients even though the device already has a CE mark and 510(k) clearance.
You may also be interested in...
Starts & Stops: Mercator Looking To Leap Into New Indications For Bullfrog Micro-Infusion Drug-Delivery
Starts & Stops is a regular feature highlighting Medtech Insight's monthly editors' picks of noteworthy medtech clinical trial announcements, initiations, completions, and suspensions. This month's edition, covering November, is led by a major milestone for Mercator Medsystems, developer of the Bullfrog micro-infusion catheter.
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions the past month or so. Over the last month, 38 new trials started, 17 trial were completed, one trial was "reinitiated," and four trials were terminated or suspended, according to Meddevicetracker.
LIMBO-ATX will evaluate adventitial delivery of dexamethasone after atherectomy-based revascularizations of lesions below the knee were noted in symptomatic patients with critical limb ischemia.